Liquid biopsy aims at simple, fast, cost-efficient, and less burdensome sample collection for cancer detection, screening, and disease monitoring; and comes with a much-appreciated clinical advantage of reduced patient morbidity and ease of longitudinal monitoring.

Growing demand for faster and earlier cancer diagnosis has brought global attention towards, CTC, a major biomarker in the liquid biopsy sample. CTC detection is a simple blood test which that allows for cancer diagnosis and has the potential to be a routine clinical practice for early cancer detection and screening.

Furthermore, advancement in technology has not only aided in the high-throughput, high-purity isolation of CTCs; but also with high specificity. The liquid biopsy market, specifically the global CTC market is estimated to show steady growth and register a healthy CAGR of 15.4% in the forecast period of 2019-2026.